Accord Healthcare launches their first biopharmaceutical product in Europe: Accofil® (filgrastim)
Accord Healthcare is pleased to announce the launch of their first European approved biopharmaceutical product Accofil®, indicated for the treatment of chemotherapy induced neutropenia. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 29, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Cost effectiveness Industry News Haematology Oncology biopharmaceutical chemotherapy induced neutropenia filgrastim hiv Latest News peripheral blood progenitor cells Source Type: news
D.C. Week: House Passes Mandate Bill, Biosimilar Gets Thumbs Up
(MedPage Today) -- Bill would restrict ACA employer mandate; FDA advisers back Neupogen copy. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 10, 2015 Category: American Health Source Type: news
Granix (Tbo-filgrastim Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 9, 2015 Category: Drugs & Pharmacology Source Type: news
FDA Advisory Committee Endorses Neupogen Biosimilar
(MedPage Today) -- Outlook good for biosimilars under abbreviated pathway. (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - January 8, 2015 Category: OBGYN Source Type: news
Biosimilar Filgrastim Recommended for Approval in US Biosimilar Filgrastim Recommended for Approval in US
A biosimilar filgrastim (Novartis) has been recommended for approval in the US, after it was found not clinically different from Amgen's Neupogen. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA panel unanimously backs Novartis' copy of Amgen's Neupogen
(Reuters) - A panel to the U.S. Food and Drug Administration unanimously backed the approval of Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen, setting the stage for the regulator's first approval of a biosimilar. (Source: Reuters: Health)
Source: Reuters: Health - January 7, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Why The FDA Panel's Nod To Sandoz's Filgrastim (Zarzio) Is Good News For Patients
The implications extend beyond cancer drugs. Biosimilars have the potential to significantly reduce the costs of modern health care for people with all kinds of illness (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 7, 2015 Category: Pharmaceuticals Authors: Elaine Schattner Source Type: news
For First Time, F.D.A. Panel Approves Generic Copy of Costly Biologic Drug
The group of experts endorsed a close version of the cancer drug Neupogen, which could open the door to more such biosimilar medicines. (Source: NYT Health)
Source: NYT Health - January 7, 2015 Category: Consumer Health News Authors: By SABRINA TAVERNISE Tags: United States Drugs (Pharmaceuticals) Food and Drug Administration Neupogen Generic Brands and Products Source Type: news
FDA Panel to Consider Biosimilar for Filgrastim
(MedPage Today) -- FDA staff are strongly supportive in pre-meeting report. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 7, 2015 Category: Primary Care Source Type: news
FDA Finds No Clinical Differences in Novartis Biosimilar of Amgen Drug
Documents released in advance of an FDA advisory meeting stated no difference between Neupogen and Sandoz biosimilar (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 6, 2015 Category: Pharmaceuticals Source Type: news
FDA staff recommends Novartis copy of Amgen's Neupogen
(Reuters) - Staff reviewers at the U.S. Food and Drug Administration recommended approval of Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen, finding no "clinically meaningful differences" between the two. (Source: Reuters: Health)
Source: Reuters: Health - January 5, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Expands Indication for Tbo-filgrastimFDA Expands Indication for Tbo-filgrastim
The granulocyte colony-stimulating factor analog can now be self-administered by patients, with the new expanded FDA indication. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
What’s the Difference Between Neulasta...
Chemotherapy can cause your neutrophil counts to drop, which puts you at risk of infection. Neutropenia is treated with Neulasta or Neupogen, but what's the difference, and how do you choose? Read more to understand your choices. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - December 25, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Novartis copy of Amgen biotech drug shows similar efficacy-study
ZURICH (Reuters) - Novartis said its copycat version of Amgen's Neupogen for patients with low white blood cell counts works as well as the original drug in a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
